Can a hepatitis drug lower dangerous liver pressure?
NCT ID NCT04863703
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study follows 11 people with chronic hepatitis B and D who also have liver cirrhosis and are already taking the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension, a dangerous buildup of pressure in the liver's blood vessels. Participants will have their liver pressure measured before and after treatment, and their quality of life will be tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bulevirtide
What this could lead to
If successful, this study could show that suppressing the hepatitis delta virus helps lower portal hypertension, potentially improving outcomes for patients with liver cirrhosis.
What could go wrong
This is a very small observational study with only 11 participants, so results may not apply broadly. It does not test a new treatment but observes an existing one, so no direct benefit is guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.